Evaxion A/S (EVAX) vs Immutep (IMMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immutep (IMMP) has outperformed Evaxion A/S (EVAX) over the past year, gaining 90.1% versus a loss of 51.5%. Over five years, IMMP leads with a -2.8% price change compared with -99.2% for EVAX. Immutep is the larger company by market cap ($28.3 million vs $27.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | IMMP |
|---|---|---|
| Share price | $3.05 | $3.84 |
| Market cap | $27.52M | $28.30M |
| 1-day change | -2.87% | -6.56% |
| YTD return | -36.06% | +34.27% |
| 1-year return | -51.51% | +90.10% |
| 5-year return | -99.23% | -2.78% |
| EPS (TTM) | $-1.00 | $-7.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $70.60 |
| 52-week low | $2.77 | $3.80 |
| Distance from 52-week high | -74.90% | -94.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.85% | +681.25% |
| Average volume | 200.14K | 14.70K |
| Shares outstanding | 9.02M | 7.37M |
| Employees | 46 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed EVAX by 141.6 percentage points over the past year.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Healthcare · Biotechnology
EVAX vs IMMP FAQ
Which is bigger, Evaxion A/S or Immutep?
Immutep (IMMP) is larger, with a market capitalization of $28.30M compared with $27.52M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, EVAX or IMMP?
IMMP returned +90.10% over the past 12 months, compared with -51.51% for EVAX (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and Immutep in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.